Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age

被引:17
作者
Cockrum, Richard H.
Soo, Jackie
Ham, Sandra A.
Cohen, Kenneth S.
Snow, Shari G. [1 ]
机构
[1] Univ Chicago Med, Dept Obstet & Gynecol, Chicago, IL 60637 USA
基金
美国国家卫生研究院;
关键词
DEPOT-MEDROXYPROGESTERONE ACETATE; ONLY CONTRACEPTION; HORMONAL CONTRACEPTION; ETHINYL ESTRADIOL; RISK; PROGESTINS; NORETHISTERONE; EPIDEMIOLOGY; THROMBOSIS; THERAPY;
D O I
10.1097/AOG.0000000000004896
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To evaluate associations between use of seven progestogens and incident acute venous thromboembolism (VTE) among women of reproductive age. METHODS: This nested matched case-control study identified women aged 15-49 years from January 1, 2010, through October 8, 2018, in the IBM MarketScan databases, a nationwide sample of private insurance claims in the United States. After exclusions, 21,405 women with incident acute VTE (case group), identified by diagnosis codes, were matched 1:5 by year of birth and index date through risk set sampling to 107,025 women without prior VTE (control group). From lowest to highest systemic dose based on a modified hierarchy, progestogens studied were levonorgestrel-releasing intrauterine device (LNG-IUD), oral norethindrone, etonogestrel implant, oral progesterone, oral medroxyprogesterone acetate, oral norethindrone acetate, and depot medroxyprogesterone acetate (DMPA). Conditional logistic regression models adjusted for 16 VTE risk factors were used to estimate odds ratios and 99% CIs for incident acute VTE associated with current progestogen use compared with nonuse. The primary analysis treated each progestogen as a binary exposure. Dose, which varied for oral formulations, and chronicity were explored separately. Significance was set at PRESULTS: Current use of higher-dose progestogens was significantly associated with increased odds of VTE compared with nonuse (oral norethindrone acetate: adjusted odds ratio [aOR] 3.00, 99% CI 1.96-4.59; DMPA: aOR 2.37, 99% CI 1.95-2.88; and oral medroxyprogesterone acetate: aOR 1.98, 99% CI 1.41-2.80). Current use of other progestogens was not significantly different from nonuse (LNG-IUD, etonogestrel implant, and oral progesterone) or had reduced odds of VTE (oral norethindrone). Sensitivity analyses that assessed misclassification bias supported the primary findings. CONCLUSION: Among reproductive-aged women using one of seven progestogens, only use of norethindrone acetate and medroxyprogesterone acetate-considered higher-dose progestogens-was significantly associated with increased odds of incident acute VTE. The roles of progestogen type, dose, and indication for use warrant further study.
引用
收藏
页码:477 / 487
页数:11
相关论文
共 54 条
[1]  
[Anonymous], 2019, OBSTET GYNECOL, V133, pE128, DOI 10.1097/AOG.0000000000003072
[3]  
[Anonymous], 2015, Medical Eligibility Criteria for Contraceptive Use
[4]   Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study [J].
Barsoum, Michel K. ;
Heit, John A. ;
Ashrani, Aneel A. ;
Leibson, Cynthia L. ;
Petterson, Tanya M. ;
Bailey, Kent R. .
THROMBOSIS RESEARCH, 2010, 126 (05) :373-378
[5]   Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic Genotypes [J].
Bergendal, Annica ;
Persson, Ingemar ;
Odeberg, Jacob ;
Sundstrom, Anders ;
Holmstrom, Margareta ;
Schulman, Sam ;
Bjorgell, Ola ;
Kieler, Helle .
OBSTETRICS AND GYNECOLOGY, 2014, 124 (03) :600-609
[6]   Risk factors for venous thromboembolism in pre- and postmenopausal women [J].
Bergendal, Annica ;
Bremme, Katarina ;
Hedenmalm, Karin ;
Larfars, Gerd ;
Odeberg, Jacob ;
Persson, Ingemar ;
Sundstrom, Anders ;
Kieler, Helle .
THROMBOSIS RESEARCH, 2012, 130 (04) :596-601
[7]   Limited knowledge on progestogen-only contraception and risk of venous thromboembolism [J].
Bergendal, Annica ;
Odlind, Viveca ;
Persson, Ingemar ;
Kieler, Helle .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2009, 88 (03) :261-266
[8]   Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed" [J].
Bjerre, LM ;
LeLorier, J .
BRITISH MEDICAL JOURNAL, 2000, 320 (7233) :503-506
[9]   Progestin-only contraception and venous thromboembolism [J].
Blanco-Molina, M. A. ;
Lozano, M. ;
Cano, A. ;
Cristobal, I. ;
Pallardo, L. P. ;
Lete, I. .
THROMBOSIS RESEARCH, 2012, 129 (05) :E257-E262
[10]   Abnormal Vaginal Bleeding in Women Desiring Contraception Who Are Taking Anticoagulation Therapy [J].
Bonnington, Adam ;
Autry, Amy M. .
OBSTETRICS AND GYNECOLOGY, 2018, 131 (04) :632-634